Cellular Senescence and Aging
Cellular Senescence and Aging
批准号:
8463938
负责人:
JAMES L. KIRKLAND
金额:
$189.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2017-04-30
关键词:
AddressAgeAgingAging-Related ProcessAnimal ModelAnimalsAttenuatedAwarenessBioinformaticsBiology of AgingBiomedical ResearchCancerousCell AgingCellsChronicChronic DiseaseClinicClinicalCollaborationsDataDeveloped CountriesDevelopmentDiseaseElderlyFaceFatty acid glycerol estersFunctional disorderGeneticGrowthHealthHematological DiseaseHumanImmune System and Related DisordersInflammationInflammatoryInstitutesInterventionLinkLongevityMalignant NeoplasmsMetabolicMichiganMolecularMusMuscleNamesNatureOncogenicOrganOrganismPathologyPathway interactionsPhenotypeProcessProgram Research Project GrantsResearch PersonnelRodentRoleSkinSterilitySystemSystems BiologyTestingTexasTissuesUniversitiesWorkage relatedbaseclinically relevantdisabilityexperiencefrailtyfunctional restorationhuman FRAP1 proteinimmune functionin vivoinhibitor/antagonistinnovationmeetingsmouse modelnovelpreventpublic health relevancesenescencetherapy designtissue/cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A challenge of biomedical research is to compress the period of frailty and disability as people reach advanced age. Cellular senescence, the growth arrest that occurs when cells experience potentially oncogenic insults, has been proposed to contribute to age-related dysfunction. There is as yet no definitive evidence for this.
To understand the role of senescent cells in age-related dysfunction, we created a mouse model from which p16-expressing senescent cells can be removed selectively. We devised mechanism-based interventions that interfere with the inflammatory senescence-associated secretory phenotype (SASP), which may be the basis of the inflammation that underlies many age-related diseases and frailty. We discovered a link between the SASP and immune system dysfunction, and found potential ways to break this link. Our unifying hypothesis is that preventing the accumulation of senescent cells or their effects can restore age-related decrements in function. We propose the following Specific Aims. Aim 1 Eliminate senescent cells. We will use an innovative animal model from which we can selectively remove senescent, potentially cancerous cells to determine if this intervention attenuates development of age-related functional decrements and frailty and enhances health span. Aim 2 Inhibit the SASP by manipulating Jak/Stat. We found the SASP is attenuated by inhibiting Jak/Stat, an intervention that dramatically reduces the frailty associated with cancer and hematological disorders. We will test the impact of this intervention on age-related dysfunction. Aim 3 Inhibit the SASP by manipulating mTOR. We also found that inhibiting components of the mTOR pathway inhibits the SASP without interfering with the senescence-associated replicative arrest that defends against cancer. We will determine whether and how this inhibition reduces age-related dysfunction. Aim 4 Break the link between the SASP and inflammasomal activation. We found the SASP activates the inflammasome, while inhibiting it restored immune function in old animals. We will test if inflammasome inhibitors reduce age-related senescent cell accumulation and dysfunction. These Aims will be tested in four Subprojects supported by Administrative, Mouse Phenotyping and Pathological Assessment (MPPA), and Systems Biology/ Bioinformatics Cores. We will use innovative culture systems, novel animal models, and comprehensive health span phenotyping to test our hypothesis, focusing on frailty/muscle, metabolic/fat, skin, and immune function initially. Our approach will provide timely, innovative, and clinically relevant interventional results based on addressing the fundamental question of the role of cellular senescence that has remained unanswered for many years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COVID-FIS: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND EXCESSIVE INFLAMMATORY RESPONSE IN OLDER ADULTS IN NURSING HOMES
-
批准号:10208138
-
项目类别:
-
资助金额:$191.79万
-
财政年份:2020
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Targeting Cellular Senescence to Extend Healthspan
-
批准号:10349480
-
项目类别:
-
资助金额:$283.54万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Targeting Cellular Senescence to Extend Healthspan
-
批准号:10561620
-
项目类别:
-
资助金额:$281.97万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Targeting Cellular Senescence to Extend Healthspan
-
批准号:10117964
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Metabolic Dysfunction
-
批准号:10561629
-
项目类别:
-
资助金额:$51.23万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Translational Geroscience Network
-
批准号:10339417
-
项目类别:
-
资助金额:$77.68万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Metabolic Dysfunction
-
批准号:10349485
-
项目类别:
-
资助金额:$50.59万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Translational Geroscience Network
-
批准号:10539281
-
项目类别:
-
资助金额:$78.43万
-
财政年份:2019
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Imaging for Cellular Senescence
-
批准号:8966806
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2015
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Geroscience Network
-
批准号:8613690
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2013
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Geroscience Network
-
批准号:8738561
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2013
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Cellular Senescence and Aging
-
批准号:8665353
-
项目类别:
-
资助金额:$203.17万
-
财政年份:2012
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Cellular Senescence and Aging
-
批准号:8847606
-
项目类别:
-
资助金额:$188.35万
-
财政年份:2012
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Cellular Senescence and Aging
-
批准号:8213831
-
项目类别:
-
资助金额:$202.89万
-
财政年份:2012
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Administrative Core
-
批准号:8259567
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2012
-
负责人:JAMES L. KIRKLAND
-
依托单位:
The Next Step in Aging Research: From Bench to Bedside
-
批准号:7908210
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Effect of Aging on Preadipocyte Differentiation
-
批准号:7907512
-
项目类别:
-
资助金额:$13.34万
-
财政年份:2009
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Regional Differences in Preadipocyte Development
-
批准号:6942572
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2003
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Regional Differences in Preadipocyte Development
-
批准号:7283367
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2003
-
负责人:JAMES L. KIRKLAND
-
依托单位:
Regional Differences in Preadipocyte Development
-
批准号:6727750
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2003
-
负责人:JAMES L. KIRKLAND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: